Study of Individualized Therapy on Hyperphosphatemia in Maintenance Hemodialysis Patients

NACompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
HyperphosphatemiaEnd-stage Renal Disease
Interventions
OTHER

enhanced individualised therapy

additional dialysis dosage, modification of medication and prescribed dietary plan

OTHER

non-enhanced individualised therapy

modified medication, prescribed dietary plan and regular three times/week dialysis dosage

OTHER

regular intervention

Phosphate binders and calcitriol would be prescribed according to the guidelines. Phosphate binders included in the study are calcium acetate, calcium carbonate or sevelamer. Dosage is based on patients serum phosphate and calcium level. Calcitriol prescribed in the study is Rocaltrol and the dosage is based on PTH, serum phosphate and calcium level. Patients' diet habit will not be altered.

Trial Locations (1)

200041

Huashan Hospital, Shanghai

All Listed Sponsors
lead

Huashan Hospital

OTHER

NCT02684643 - Study of Individualized Therapy on Hyperphosphatemia in Maintenance Hemodialysis Patients | Biotech Hunter | Biotech Hunter